MedPath

AbViro LLC

🇺🇸United States
Ownership
Private
Established
2014-05-08
Employees
11
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:1

Trial Phases

2 Phases

Phase 1:1
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (50.0%)
Phase 2
1 (50.0%)

A Study to Evaluate the Safety and Efficacy of AV-1 Against Dengue Virus 3 (DENV-3) Infection

Phase 2
Recruiting
Conditions
DENV-3 Controlled Human Infection Model
Interventions
Drug: AV-1 100 mg
Drug: AV-1 300 mg
Drug: AV-1 900 mg
Drug: Placebo
First Posted Date
2025-01-29
Last Posted Date
2025-07-08
Lead Sponsor
AbViro LLC
Target Recruit Count
84
Registration Number
NCT06799741
Locations
🇺🇸

Center for Immunization Research Inpatient Unit, Baltimore, Maryland, United States

🇺🇸

Center for Immunization Research (CIR) JHBSPH, Baltimore, Maryland, United States

🇺🇸

UVM Larner College of Medicine Department of MMG, Burlington, Vermont, United States

A Study to Determine the Safety of AV-1, an Antibody Being Developed for Treatment of Dengue, in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
Drug: Placebo
First Posted Date
2020-02-18
Last Posted Date
2022-10-31
Lead Sponsor
AbViro LLC
Target Recruit Count
42
Registration Number
NCT04273217
Locations
🇺🇸

PPD Austin Clinic, 7551 Metro Center Drive, Suite 200, Austin, Texas, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.